Current investigative and clinical experience with alendronate in osteoporosis

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.

Original languageEnglish
Pages (from-to)103-118
Number of pages16
JournalToday's Therapeutic Trends
Volume14
Issue number2
StatePublished - 1996
Externally publishedYes

Fingerprint

Alendronate
Osteoporosis
Bone Resorption
Bone Remodeling
Diphosphonates
Bone Density
Incidence
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Current investigative and clinical experience with alendronate in osteoporosis. / Recker, Robert R.

In: Today's Therapeutic Trends, Vol. 14, No. 2, 1996, p. 103-118.

Research output: Contribution to journalReview article

@article{ddaee4ecc2c74c94b8d7b8899fa58f5a,
title = "Current investigative and clinical experience with alendronate in osteoporosis",
abstract = "The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.",
author = "Recker, {Robert R.}",
year = "1996",
language = "English",
volume = "14",
pages = "103--118",
journal = "Today's Therapeutic Trends",
issn = "0741-2320",
publisher = "Communications Media for Education,Inc",
number = "2",

}

TY - JOUR

T1 - Current investigative and clinical experience with alendronate in osteoporosis

AU - Recker, Robert R.

PY - 1996

Y1 - 1996

N2 - The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.

AB - The bisphosphonates represent a new class of pharmacologic agents that inhibit bone resorption and decrease the rate of bone turnover, making them of potential clinical value in the treatment of osteoporosis. Among these drugs, the new aminobisphosphonate alendronate (Fosamax(TM)) preferentially inhibits bone resorption at doses that do not inhibit mineralization, thus permitting continuous administration. In extensive clinical use, alendronate has been shown to reduce the turnover, and increase the density, of bone, and reduces the incidence of new vertebral fractures and loss of height in osteoporotic postmenopausal women.

UR - http://www.scopus.com/inward/record.url?scp=0029827533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029827533&partnerID=8YFLogxK

M3 - Review article

VL - 14

SP - 103

EP - 118

JO - Today's Therapeutic Trends

JF - Today's Therapeutic Trends

SN - 0741-2320

IS - 2

ER -